AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial
Resource Type
Article
Authors
Martinelli, Giovanni ; Santoro, Armando ; Gambacorti-Passerini, Carlo ; Polo, Susana Vives ; Solomon, Scott R. ; Mukherjee, Sudipto ; Lech-Maranda, Ewa ; Levy, Moshe Yair ; Wierzbowska, Agnieszka ; Calbacho-Robles, María ; Marconi, Giovanni ; Giannini, Maria Benedetta ; Cano, Isabel ; Miñana, Laura Torres ; Acuña-Cruz, Evelyn ; Angelosanto, Noemi ; Mughal, Tariq I. ; Galleu, Antonio ; Blotta, Simona ; Ravandi, Farhad ; Montesinos, Pau
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S243-S244
Subject
Language
ISSN
2152-2650